| Authors: |
Brennan RJ; Sanofi, Cambridge, MA, USA. richbrennan@gmail.com., Jenkinson S; Pfizer, La Jolla, CA, USA.; Metrion Biosciences, San Diego, CA, USA., Brown A; GSK, Stevenage, UK., Delaunois A; UCB Biopharma, Braine-l'Alleud, Belgium., Dumotier B; Novartis Biomedical Research, Basel, Switzerland., Pannirselvam M; Vertex Pharmaceuticals, Boston, MA, USA.; GSK, Waltham, MA, USA., Rao M; Janssen Research & Development, San Diego, CA, USA.; Neurocrine Biosciences, San Diego, CA, USA., Ribeiro LR; UCB Biopharma, Braine-l'Alleud, Belgium.; AstraZeneca, Cambridge, UK.; Grunenthal, Berkshire, UK., Schmidt F; Sanofi, Frankfurt, Germany., Sibony A; UCB Biopharma, Braine-l'Alleud, Belgium., Timsit Y; Novartis Biomedical Research, Cambridge, MA, USA.; Blueprint Medicines, Cambridge, MA, USA., Sales VT; Takeda Pharmaceuticals, Cambridge, MA, USA., Armstrong D; Novartis Biomedical Research, Cambridge, MA, USA.; Armstrong Pharmacology, Macclesfield, UK., Lagrutta A; Merck, North Wales, PA, USA., Mittlestadt SW; AbbVie, North Chicago, IL, USA., Naven R; Takeda Pharmaceuticals, Cambridge, MA, USA.; Novartis Biomedical Research, Cambridge, MA, USA., Peri R; Takeda Pharmaceuticals, Cambridge, MA, USA.; Alexion Pharmaceuticals, Wilmington, DE, USA., Roberts S; Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland., Vergis JM; Faegre Drinker Biddle and Reath, LLP, Washington, DC, USA., Valentin JP; UCB Biopharma, Braine-l'Alleud, Belgium. |
